Corticosteroids in rheumatoid arthritis: Is a trial of their 'disease modifying' potential feasible?

M. A. Byron, J. R. Kirwan

Research output: Contribution to journalArticle (Academic Journal)peer-review

26 Citations (Scopus)


After three decades of experience the use of corticosteroids to treat rheumatoid arthritis (RA) remains a matter of personal taste and generates much debate. Although their role in life threatening complications is apparently acceptable, one standard text suggests that less than 5% of patients with predominantly articular disease will require them, and in a recent survey British rheumatologists reported using corticosteroids only 'occassionally' or 'very infrequently'. However, when making clinical decisions a physician's opinion does not necessarily reflect his clinical practice. Recent studies have found that 24 of 100 consecutive RA patients seen lat one British hospital were taking a mean daily dose of 5.6 mg of prednisolone2 and that 15% of outpatients seen at a Dutch clinic were also receiving steroid treatment.

Original languageEnglish
Pages (from-to)171-173
Number of pages3
JournalAnnals of the Rheumatic Diseases
Issue number2
Publication statusPublished - 1 Jan 1986


Dive into the research topics of 'Corticosteroids in rheumatoid arthritis: Is a trial of their 'disease modifying' potential feasible?'. Together they form a unique fingerprint.

Cite this